ARTL - שווי שוק לנפח מכירות Artelo Biosciences Inc.

Artelo Biosciences develops endocannabinoid system modulators to combat fibrosis and cancer-related anorexia. On GURU.Markets, the market capitalization-to-revenue ratio clearly visualizes the asset's dynamics, where this metric equals . However, strict government regulation and pressure from pharma behemoths create risks. The situation is further complicated by a lack of profit and a high cash burn rate on R&D processes.

To assess the credit quality of Artelo Biosciences (ARTL), the analyst examines the price-to-sales ratio trend, which determines the market value of every dollar of revenue and helps identify the risk of overpaying for the asset. Stable utilization of contract manufacturing plants for cannabinoid production confirms operational resilience, which, combined with this indicator, helps the investor understand the extent to which current capitalization aligns with actual revenue generation rates.